The aim of this study is to determine whether metabolites included in an extensive MS metabolomics platform can improve the prediction of six common pregnancy outcomes (GDM, PE, GHT, SGA, LGA and sPTB) over established risk factors alone. Here, SPTB is linked to gestational diabetes.